pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Novartis faces another setback while Novo drops Nordisk partnership

Sep 19, 2026·read at Endpoints ↗Negative

The latest edition of Endpoints Weekly notes that Novartis experienced another failure, though the newsletter does not provide details about the product or trial.

It also reports that Novo Nordisk has removed the “Nordisk” branding from its communications, indicating a shift in its branding strategy.

The brief update invites readers to view recordings of a recent China event in Washington, D.C., and encourages sign‑ups for full access, but no further substantive information is given.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Another Novartis failure; Novo drops the ‘Nordisk’; and more”

read at Endpoints ↗
80 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVARTIS2NOVO2Novo Nordisk Inc

related stories

  • 2d agoSionna says good-bye to 46% of staffers, including execBioSpace
  • Sep 10STAT+: The gifts from pharma companies that keep on givingSTAT
  • Sep 10STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and moreSTAT
  • Sep 10STAT+: Cancer medicines remain in short supply across the U.S., survey findsSTAT
  • Sep 9STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and moreSTAT